Abstract:Study Objectives: To compare clinical, electrophysiologic, and biologic data in narcolepsy without cataplexy with low (<= 110 pg/ml), intermediate (110-200 pg/ml), and normal (> 200 pg/ml) concentrations of cerebrospinal fluid (CSF) hypocretin-1. Setting: University-based sleep clinics and laboratories. Patients: Narcolepsy without cataplexy (n = 171) and control patients (n = 170), all with available CSF hypocretin-1. Design and interventions: Retrospective comparison and receiver operating characteristics curve analysis. Patients were also recontacted to evaluate if they developed cataplexy by survival curve analysis. Measurements and Results: The optimal cutoff of CSF hypocretin-1 for narcolepsy without cataplexy diagnosis was 200 pg/ml rather than 110 pg/ml (sensitivity 33%, specificity 99%). Forty-one patients (24%), all HLA DQB1*06:02 positive, had low concentrations (<= 110 pg/ml) of CSF hypocretin-1. Patients with low concentrations of hypocretin-1 only differed subjectively from other groups by a higher Epworth Sleepiness Scale score and more frequent sleep paralysis. Compared with patients with normal hypocretin-1 concentration (n = 117, 68%), those with low hypocretin-1 concentration had higher HLA DQB1*06:02 frequencies, were more frequently non-Caucasians (notably African Americans), with lower age of onset, and longer duration of illness. They also had more frequently short rapid-eye movement (REM) sleep latency (<= 15 min) during polysomnography (64% versus 23%), and shorter sleep latencies (2.7 +/- 0.3 versus 4.4 +/- 0.2 min) and more sleep-onset REM periods (3.6 +/- 0.1 versus 2.9 +/- 0.1 min) during the Multiple Sleep Latency Test (MSLT). Patients with intermediate concentrations of CSF hypocretin-1 (n = 13, 8%) had intermediate HLA DQB1*06:02 and polysomnography results, suggesting heterogeneity. Of the 127 patients we were able to recontact, survival analysis showed that almost half (48%) with low concentration of CSF hypocretin-1 had developed typical cataplexy at 26 yr after onset, whereas only 2% had done so when CSF hypocretin-1 concentration was normal. Almost all patients (87%) still complained of daytime sleepiness independent of hypocretin status. Conclusion: Objective (HLA typing, MSLT, and sleep studies) more than subjective (sleepiness and sleep paralysis) features predicted low concentration of CSF hypocretin-1 in patients with narcolepsy without cataplexy.

Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2

Hla-Dpb1 and Hla Class I Confer Risk of and Protection from Narcolepsy

Narcolepsy risk loci are enriched in immune cells and suggest autoimmune modulation of the T cell receptor repertoire

High‐resolution HLA sequencing and hypocretin receptor 2 autoantibodies in narcolepsy type 1 and type 2

0627 Influenza HA Antibody Titers in Recent Onset Type-1 Narcolepsy

Monoclonal antibody against H1N1 influenza virus hemagglutinin cross reacts with hnRNPA1 and hnRNPA2/B1

In vivo clonal expansion and phenotypes of hypocretin-specific CD4+ T cells in narcolepsy patients and controls

Genome wide analysis of narcolepsy in China implicates novel immune loci and reveals changes in association prior to versus after the 2009 H1N1 influenza pandemic.

Cell-based versus enzyme-linked immunosorbent assay for detection of anti-Tribbles homolog 2 autoantibodies in Chinese patients with narcolepsy

Absence of specific autoantibodies in patients with narcolepsy type 1 as indicated by an unbiased random peptide-displayed phage screening

Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy.

Identification of Antibodies Targeting the H3N2 Hemagglutinin Receptor Binding Site following Vaccination of Humans

Narcolepsy Onset is Seasonal and Increased Following the 2009 H1N1 Pandemic in China

Infection, vaccination and narcolepsy type 1: Evidence and potential molecular mechanisms

Hypocretin (orexin) Neuropeptide Precursor Gene, HCRT, Polymorphisms in Early-Onset Narcolepsy with Cataplexy.

Downregulation of hypocretin/orexin after H1N1 Pandemrix vaccination of adolescent mice

Ventilatory Chemoresponsiveness, Narcolepsy-Cataplexy and Human Leukocyte Antigen DQB1*0602 Status

Analysis of polyclonal and monoclonal antibody to the influenza virus nucleoprotein in different oligomeric states

Hypothalamic immunopathology in anti-Ma-associated diencephalitis with narcolepsy-cataplexy

Sleepiness That Cannot Be Overcome: Narcolepsy And Cataplexy

Identification and Structure of a Multidonor Class of Head-Directed Influenza-Neutralizing Antibodies Reveal the Mechanism for Its Recurrent Elicitation